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Abstract. Lung cancer is the leading cause of cancer-related
death worldwide, with approximately 1.2 million deaths
annually. The standard-of-care in patients with advanced
disease is platinum-based doublet chemotherapy. Recent
advances in the understanding of biological mechanisms of
tumor growth have allowed for identification of some molecular
targets for cancer treatment, such as vascular endothelial
growth factor (VEGF) and epidermal growth factor receptor
(EGFR). VEGF is a pro-angiogenetic factor, which binds
membrane receptors, and whose intra-cytoplasmatic domain
presents tyrosine kinase activity. Pathological angiogenesis
promotes tumor growth and metastasis. Targeted action against
angiogenesis can lead to regression or normalization of
neovascular structures and to inhibition of new blood vessel
growth. The most commonly used mechanism is mediated by
bevacizumab, a monoclonal antibody that selectively binds to
VEGF and prevents interaction with its receptor. Currently
bevacizumab is the only anti-angiogenic agent approved for the
first-line treatment of non-small cell lung cancer (NSCLC) in
selected patients. In the present review, we discuss the most
important trials that demonstrate the efficacy and safety of
bevacizumab. We also present an overview of the types of
patients eligible for this treatment and a cost-effectiveness
analysis. In conclusion, the possibility of administering a
treatment with bevacizumab must be carefully analyzed case by
case. It is important to identify those patients who can really
benefit from the use of this drug, through the identification of
specific response markers.
Lung cancer is the leading cause of cancer-related death
worldwide, with approximately 1.2 million deaths annually.
More than 80% of lung cancer cases are of non-small cell
cancer (NSCLC). Approximately 51% of patients present
with advanced disease at diagnosis (1).
Currently, the treatment of NSCLC is undergoing
significant progress due to the continuous evolution of
chemotherapy drugs and the introduction of new targeted
agents. However, most patients cannot benefit from the most
effective therapeutic combinations because of several factors,
such as age, which is often advanced, and their general
clinical condition (2). The standard-of-care in patients with
advanced disease is platinum-based doublet chemotherapy.
Various studies comparing different platinum-based doublets
have been conducted, without finding superiority of one
schedule with respect to any other. The addition of a third
cytotoxic agent increases toxicity and does not provide for
additional clinical benefit (3). Even if chemotherapy has
improved the outcome and the quality of life of patients,
prognosis remains unfavorable, with a median survival time
that does not exceed 10 months (1).
Recent advances over the understanding of biological
mechanisms of tumor growth have allowed identification of
certain molecular targets for cancer treatment. In particular,
in NSCLC, we have sharpened knowledge regarding specific
growth factors such as vascular endothelial growth factor
(VEGF) and epidermal growth factor (EGF) (4).
VEGF is a pro-angiogenetic factor which binds membrane
receptors, and whose intra-cytoplasmatic domain has
tyrosine kinase activity. Angiogenesis is the growth of new
microvessels from pre-existing vessels. Many different cells
are involved in this process, such as macrophages,
endothelial cells and pericytes, and these are coordinated by
a fine balance between pro-angiogenic and anti-angiogenic
factors (5, 6). Pathological angiogenesis promotes tumor
growth and metastasis. (7) Tumor angiogenesis is
characterized by the formation of abnormal, tortuous, dilated,
poorly-organized vessels with altered permeability (8-10).
These vascular abnormalities lead to formation of a
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microenvironment characterized by interstitial hypertension,
hypoxia and acidosis, with a consequent increased
production of VEGF (11, 12).
Targeted action against angiogenesis can lead to regression
or normalization of neovascular structures and the inhibition
of new blood vessel growth. This can be obtained by acting
on the VEGF pathway by inhibiting its ligand or its receptor
(13). The most commonly used method uses a monoclonal
antibody that selectively binds VEGF and prevents
interaction with its receptor. This antibody is called
bevacizumab. It is currently indicated in combination with
platinum-based chemotherapy in the first-line treatment of
unresected, advanced, metastatic or recurrent NSCLC with
non-squamous cell histology. (14)
Efficacy Results
Bevacizumab is the only anti-angiogenic agent approved for
the first-line treatment of NSCLC in selected patients (13,
14). Bevacizumab efficacy was recently demonstrated in a
number of important clinical trials (15-17, 19-22) (Table I).
In 2004, Johnson et al. conducted a randomized phase II
trial comparing the chemotherapy doublet carboplatin-
paclitaxel versus the same chemotherapy regimen plus
bevacizumab, at a dose of 7.5 or 15 mg/kg. Patients who
received high-dose bevacizumab compared to those who
received chemotherapy-alone had a higher response rate (RR)
(31.5% vs. 18.8%), longer time-to-progression (TTP) (74
months vs. 4.2 months; p=0.023) and increased overall
survival (OS) (17.7 months vs. 14.9 months; p=0.63). In this
trial, a higher rate of hemoptysis was observed among patients
treated with bevacizumab. It was apparently associated with
squamous cell histology, cavitated lesions, centrally-located
tumors, or close proximity to major blood vessels (15).
In 2006, the Eastern Cooperative Oncology Group
(ECOG) conducted a large randomized phase III trial
(E4599), enrolling 878 patients with stage IIIB-IV non-
squamous NSCLC. Patients were treated with carboplatin-
paclitaxel every three weeks for six cycles with or without
bevacizumab at 15 mg/kg. Bevacizumab was then
administered as maintenance therapy until evidence of
disease progression or unacceptable toxicity occurred. In
patients treated with bevacizumab overall survival (OS) was
significantly longer (12.3 months vs. 10.3 months; p=0.003),
increased progression-free survival (PFS) (6.2 months vs. 4.5
months; p<0.001) and a higher objective RR (35% vs. 15%;
p<0.001). The experimental regimen was well-tolerated,
although more major bleeding episodes were observed than
in the control group (4.4% vs. 0.7%) (16).
In the phase III AVAiL trial (Avastin in Lung trial), patients
were randomized to receive a chemotherapeutic treatment
with cisplatin and gemcitabine, with or without bevacizumab
at two different doses, 15 mg/kg and 7.5 mg/kg. This study
showed a significant improvement in the primary end-point
of PFS with the addition of high-dose bevacizumab compared
to chemotherapy-alone (6.5 months vs. 6.1 months; p=0.03),
or by the addition of low-dose bevacizumab (6.7 months vs.
6.1 months; p=0.003). The RR in the group of patients
receiving high-dose or low-dose bevacizumab or placebo of
30.4%, 34.1% and 20.1% respectively. The results in terms
of OS were not statistically significant in the chemotherapy
group or in the high-dose bevacizumab group (13.1 months
vs. 13.4 months; p=0.761), nor in the low-dose bevacizumab
group (13.1 months vs. 13.6 months; p=0.42) (17). A
retrospective analysis on data of this study showed a benefit
in terms of PFS using bevacizumab maintenance
monotherapy compared to the control group (4.6 months vs.
3.2 months), but did not show a benefit in terms of OS (18).
Adverse events appeared more frequently in the groups
treated with bevacizumab. These were, more frequently,
hypertension (7% in the low-dose group and 9% in the high-
dose group vs. 2% in the control group), proteinuria (2% and
3% vs. 0%) and bleeding (4% and 5% vs. 2%) (17).
The efficacy of bevacizumab was also studied by Patel et
al. in a phase II study published in 2009. In that study,
patients with NSCLC received a first-line treatment with
pemetrexed, carboplatin, and bevacizumab, followed by
maintenance therapy with the doublet pemetrexed-
bevacizumab. Patel et al. enrolled 49 patients and obtained
an RR of 55%, a PFS of 7.8 months and an OS of 14.1
months (19). In light of the data from this study, the phase III
POINTBREAK trial was conducted, in which 939 patients
were randomized into two treatment arms. In the first arm,
patients were treated with pemetrexed-carboplatin-
bevacizumab, followed by pemetrexed plus bevacizumab in
maintenance therapy. In the second arm, patients were,
however, treated according to the scheme paclitaxel-
carboplatin-bevacizumab followed by maintenance therapy
with bevacizumab alone. This study did not reach statistical
significance for the primary end-point of OS (12.6 months
vs. 13.4 months, p=0.949), although in the group treated
with pemetrexed and bevacizumab in maintenance therapy,
an increased PFS was reported (6 months vs. 5.6 months,
p=0.012) (20, 21).
Another important phase III trial was AVAPERL, in which
after four cycles of chemotherapy with cisplatin, pemetrexed,
and bevacizumab, patients were randomized to receive
maintenance therapy with bevacizumab alone or with
pemetrexed and bevacizumab. This trial showed an
advantage over the primary end-point of PFS in the group
receiving maintenance therapy with the doublet of drugs (6.6
months vs. 10.2 months, p<0.001). There was also an
improvement in OS in patients treated with pemetrexed and
bevacizumab in maintenance therapy (19.8 months vs. 15.9
months; p=0.39), but the result was not statistically
significant (22, 23).
ANTICANCER RESEARCH 34: 1537-1546 (2014)
1538
There are also several studies that evaluated the
association of bevacizumab with platinum-based doublets in
first-line treatment (24-40). Some of these were combined
with bevacizumab regimes different from those generally
used. For example, Reynolds et al. analyzed the association
nabpaclitaxel-carboplatin-bevacizumab in a phase II study on
50 patients, obtaining a 50% RR, 9.8 months of PFS and
16.8 months of OS (32).
Interesting studies were recently conducted using
bevacizumab in lines subsequent to the first, such as the
study of Ohyangi et al. who analyzed the association
between taxotere and bevacizumab in second line or more,
obtaining a disease control rate (DCR) of 96% (41). Habib
et al., instead, analyzed weekly paclitaxel (80 mg/m2) in
combination with bevacizumab every 21 days until disease
progression or unacceptable toxicity in fourth-line treatment
or more, obtaining 40% partial responses, 35% stable disease
and 25% progression disease (42).
In the ongoing phase IIIb AvaALL trial, bevacizumab is
used as maintenance therapy after disease progression.
Expected results showed an OS beyond PD of 10.1 months
in the experimental arm, receiving bevacizumab plus a
second-line agent between pemetrexed, docetaxel or
erlotinib, versus 7.9 months in the control arm, receiving
only the second-line agent chosed by the investigator (43).
Bevacizumab was studied in combination with erlotinib in
a phase II trial conducted by West et al. (38), with S-1, an
oral fluoropyrimidine, in two studies conducted by Yoshino
et al. (39) and Kaneda et al. (40). In these studies, good
results in terms of RR, DCR and PFS were obtained, with an
acceptable toxicity profile. These associations, however,
require additional clinical trials to confirm the results.
In conclusion, treatment with bevacizumab in selected
patients with NSCLC was effective in terms of PFS and OS,
although of only a few months. It is also possible to perform
a maintenance treatment with bevacizumab, resulting in an
advantage in terms of survival and quality of life. Clinical
trials are on-going to determine the efficacy of maintenance
bevacizumab-alone or in combination with pemetrexed.
Furthermore, several studies aim to demonstrate the efficacy
of bevacizumab in combination with drugs other than those
classically used, or in lines of treatment subsequent to the
first. The promising results obtained, however, require for
additional clinical studies.
Safety Results
Adverse events most frequently observed during treatment
with bevacizumab include hypertension, nephrotic syndrome,
bleeding, gastrointestinal perforation, heart failure and
neutropenia (44).
Two large cohort studies focused on bevacizumab safety:
the SAiL (Safety of Avastin in Lung) and ARIES (Avastin
Registry: Investigation of Effectiveness and Safety) trials (45,
46). SAiL was a phase IV trial, performed on 2,212 patients,
evaluating the safety of bevacizumab in first-line treatment
at a dose of 7.5 mg/kg and 15 mg/kg, in combination with
standard chemotherapy for a maximum of six cycles,
followed by bevacizumab-alone until disease progression or
unacceptable toxicity occurs. Significant adverse events
(grade 3 or more) were rare: bleeding was observed in 80
cases (4%), pulmonary hemorrhages in 15 cases (1%),
hypertension in 125 cases (6%), proteinuria in 67 cases (3%)
and venous thromboembolism in 172 cases (8%) (45).
Lauro et al: Bevacizumab-based Treatment in NSCLC (Review)
1539
Table I. Results from phase II and III trials of bevacizumab in combination with chemotherapy as first-linetreatment.
Reference Phase Primary Regimen No. of RR PFS OS Maintenance
endpoint patients (%) (months) (months)
Johnson et al. 2004 (15) II TTP CBDCA + PTX 32 18.8 (TTP) 4.2 14.9 No
CBDCA + PTX + Bev (7.5 mg/kg) 32 28.1 (TTP) 4.3 11.6
CBDCA + PTX + Bev (15 mg/kg) 35 31.5 (TTP) 7.4 17.7
Patel et al. 2009 (19) II PFS CBDCA + Pem + Bev (15 mg/kg)  49 55 7.8 14.1 Yes
Reynolds et al. 2009 (32) II RR nabPTX + CBDCA + Bev (15 mg/kg) 50 31 9.8 16.8 No
Sandler et al. 2006 (16) III OS CBDCA + PTX 444 15 4.5 10.3 Yes
CBDCA + PTX + Bev (15 mg/kg)  434 35 6.2 12.3
Reck et al. 2009 (17) III OS CDDP + Gem   327 20.1 6.1 13.1 Yes
CDDP + Gem + Bev (15 mg/kg)  329 30.4 6.5 13.4
CDDP + Gem + Bev (7.5 mg/kg)  330 34.1 6.7 13.6
Barlesi et al. 2011 (22) III PFS CDDP + Pem +Bev (7.5 mg/kg) → Pem+Bev 125 - 10.2 19.8 Yes
CDDP + Pem + Bev (7.5 mg/kg) → Bev 128 - 6.6 15.9
Patel et al. 2012 (20, 21) III OS CBDCA + Pem +Bev (15 mg/kg) → Pem+Bev 524 - 6 12.6 Yes
CBDCA + PTX + Bev (15 mg/kg) → Bev 522 - 5.6 13.4
RR: Response rate; PFS: progression-free survival; TTP: time-to-progression; OS: overall survival; Bev: bevacizumab; CBDCA: carboplatin; CDDP:
cisplatin; Gem: gemcitabine; PTX: paclitaxel; TXT: docetaxel; Pem: pemetrexed.
The ARIES trial was conducted on 1,518 patients with
NSCLC, treated with first-line standard chemotherapy in
combination with bevacizumab. In the studied population,
hypertension was observed in 3.8% of cases, while bleeding
of more than grade 3 was observed in 1.9% of cases
(gastrointestinal in 1.1% of cases, pulmonary hemorrhage in
0.7% and CNS hemorrhage in 0.1%) (46).
The ATLAS trial on maintenance bevacizumab and
erlotinib (47), the PASSPORT trial on bevacizumab in
combination with chemotherapy in first- or second-line
treatment (48) and the BeTa trial on bevacizumab and
erlotinib in second-line treatment (49) included patients with
treated brain metastases or in therapy with anti-coagulants.
In these three trials, a low rate of adverse events was
observed, proving that patients with treated brain metastases
or patients taking anti-coagulants could be eligible for
treatment with bevacizumab (47, 48). Besse et al. in the
BRAIN trial enrolled patients affected by NSCLC with
untreated and asymptomatic brain metastases. The results
obtained showed adverse event rates comparable to those
seen in previous studies on bevacizumab (50).
Therefore, we can conclude that bevacizumab is a safe
drug with an acceptable toxicity profile. Reck et al., in a
review published in 2012 in the Annals of Oncology, claim
that the only exclusion criteria for treatment with
bevacizumab are squamous histology and hemoptysis of
grade 2 or more. Central location of the tumor, the presence
of a cavitation, anti-coagulant treatment and the presence of
brain metastases should not be considered contraindications
to treatment with bevacizumab (51).
Patient Selection
The choice of a first-line treatment containing bevacizumab
may mean choosing a therapeutic strategy that allows other
drugs to be kept for use in successive lines of treatment, such
as pemetrexed. Bevacizumab use has also the advantage of
giving the patient the possibility of a maintenance therapy
with monoclonal antibody alone. This opportunity is feasible
if there is evidence of response or stability of disease at the
end of first-line therapy. In this way, we can delay the
progression of disease and the beginning of a second-line
treatment. A therapeutic strategy containing bevacizumab is
feasible in selected patients because of the toxicity related to
the administration of bevacizumab (1).
The randomized phase II trial conducted by Johnson et al.
in 2004 showed a high rate (9.1%) of severe pulmonary
hemorrhage, fatal in some cases (15). This adverse event was
more frequent in patients with tumors with squamous cell
histology. Considering that squamous cell tumors are more
likely centrally located and cavitated compared to
adenocarcinoma, it is not clear whether this histology is an
independent risk factor or a marker of increased risk (15).
The phase II BRIDGE trial enrolled patients with squamous
cell cancer and excluded patients with severe hemoptysis and
cavitation. In only 3.2% of cases pulmonary hemorrhage
occur. Bevacizumab use in squamous NSCLC remains
experimental (52).
In many studies, squamous cell histology, a history of
hemoptysis, the presence of thrombophilic or bleeding
diathesis and the use of anti-coagulant agents became
exclusion criteria for the administration of bevacizumab.
With these restrictions, the incidence of bleeding was
reduced to about 2% in the AVAiL trial. In that study,
approximately 9% of the patients had started anticoagulant
therapy during the treatment for the occurrence of deep
venous thrombosis (17). In the phase IV SAiL trial, 15% of
enrolled patients were receiving anticoagulant therapy (45).
The incidence of bleeding in these two studies was similar
in patients receiving anticoagulants versus those not
receiving anticoagulant therapy (17, 45).
A phase II trial conducted by Johnson et al. suggested that
a central tumor location may be a risk factor for pulmonary
hemorrhage in bevacizumab-treated patients (15).
Subsequent data do not support this result. For example, in
the SAiL trial, the incidence of pulmonary hemorrhage of
any grade was 8.1% in patients with central tumors and 8.6%
in patients with no central tumor (53). In the the ARIES trial,
the rate of grade 3 or more pulmonary hemorrhage was 1.2%
in patients with centrally-located tumors compared to 0.5%
in patients without central location. However, this result was
not significantly associated with central location (54).
Sandler et al. in 2009 conducted a retrospective analysis
of the E4599 study and they observed that the main risk
factor for the occurrence of pulmonary hemorrhage was
cavitation of the primary tumor and not central location of
the cancer (55). Other data do not show a relationship
between cavitation and pulmonary hemorrhage. Cavity
formation occurred in approximately 16% of patients with
no pre-existing cavitation and was more frequent in patients
with squamous cell cancer and current smokers (56). This is
due to the central necrosis of lesions after inhibition of
angiogenesis (56). In accordance with this observation,
hemoptysis was associated with tumor size, but not with
cavitation (56).
Another widely analyzed aspect related to the risk of
bleeding is that related to the presence of brain metastases, a
factor long considered an exclusion criterion for treatment
with bevacizumab. On this topic, several clinical trials have
been conducted. For example the ATLAS, PASSPORT and
BeTa trials included patients with treated brain metastases
and recorded a low rate of CNS hemorrhage (47-49). Besse
et al. published the results of a retrospective analysis
conducted on the data of 17 studies on the use of
bevacizumab in lung, breast, kidney and colorectal cancer in
patients with untreated brain metastases. This retrospective
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analysis showed that the use of bevacizumab in patients with
brain metastases does not increase risk of bleeding (57).
Besse et al. also conducted the phase II non-comparative
BRAIN trial, enrolling patients with untreated brain
metastases. In that study, they registered a rate of CNS
hemorrhage comparable to that of previous bevacizumab
studies, in which the presence of untreated brain metastases
was an exclusion criterion (50).
Moreover, we have to take into account that bevacizumab
is responsible for an increase in blood pressure, both in
patients with a history of hypertension and in those with no
history. The pathogenesis of hypertension must be related to
the reduction of capillary network and to the blockade of
human VEGF. It leads to a reduced production of nitric oxide
and to reduced renal sodium excretion, finally resulting in an
increased plasma volume (58, 59). In 2010, Dahlberg et al.
published a retrospective analysis on the data of E4599 trial,
suggesting a positive correlation between the occurrence of
hypertension during treatment with bevacizumab and OS (15.9
months vs. 11.5 months) or PFS (7.0 months vs. 5.5 months)
(60). Similar results, also reported in the CALGB 90206 trial,
involving patients with metastatic renal cell carcinoma, were
not confirmed by later studies (61).
Finally, we analyze the aspect of patient age. We can
affirm that the risk of bleeding in elderly patients is not
increased compared to younger patients. This statement is
supported by the results of sub-group analysis of the AVAIL,
SAiL and ARIES studies (51, 54, 62).
We can conclude, however, that in some studies many
adverse events were observed during therapy with
bevacizumab, the most recent studies showed that this drug
is safe. Many of the factors previously considered exclusion
criteria, such as anticoagulant treatment, central tumor
location, the presence of cavitation, the presence of brain
metastases and advanced age, are not currently valid.
Currently, the only exclusion criteria are squamous histology
and the presence of hemoptysis (51).
Cost-effectiveness Analysis
Bevacizumab is quite an expensive molecular targeted drug.
Considering the growing necessity to reduce healthcare costs,
several cost-effectiveness analysis of chemotherapy regimens
containing bevacizumab in NSCLC were conducted. This
question is much debated in literature and conclusive results
have not yet been reached (63-66).
Here we present a review of literature of pharmaco-
economical studies, comparing a bevacizumab-containing
regimen with chemotherapy alone, for a maximum of six
cycles and with the administration of bevacizumab as
maintenance therapy in cases of response or disease stability
until disease progression or unacceptable toxicity (63-66).
Isla et al. analyzed different schemes, both of first- and
second-line, and observed a reduction of direct costs using
bevacizumab (67). Bischoff et al., who focused their
attention on the comparison of cisplatin-gemcitabine-
bevacizumab vs. cisplatin-pemetrexed, obtained similar
results (64). Stanisic et al. analyzed indirect costs in addition
to direct costs. They recorded a gain in terms of increased
productivity (reduction of indirect costs) in the arm of
patients treated with regimens containing bevacizumab. This
can be attributed to the increase of PFS and the improvement
of quality of life (69). Klein et al. analyzed first-line and
maintenance regimens containing bevacizumab 15 mg/kg and
concluded that these schemes are not cost-effective compared
to pemetrexed-based regimens (70, 71). Giuliani et al. (72)
and Ahn et al. (73) concluded that schemes based on
bevacizumab at a dose of 7.5 mg/kg in combination with
cisplatin and gemcitabine are convenient compared to
schemes based on cisplatin and pemetrexed. Finally, Goulart
and Ramsey analyzed the cost-effectiveness of cisplatin-
pemetrexed alone or in combination with bevacizumab at a
dose of 15 mg/kg. They concluded that regimens containing
bevacizumab are not cost-effective (74).
Published studies are heterogeneous for different aspects
such as the line of treatment, as certain studies included lines
following the first, the dose of bevacizumab (7.5 mg/kg or 
15 mg/kg), the analysis of the direct (cost of drugs, costs related
to the management of adverse events and increased survival)
and indirect costs (costs related to loss of productivity in terms
of work, cost of caregiver, etc.). Regarding the question of the
dose of bevacizumab, 7.5 mg/kg in some studies and 15 mg/kg
in others, the discrepancy is probably due to an absence of clear
guidelines. In fact the use of bevacizumab at the dose of 
15 mg/kg has been approved by the Food and Drug
Administration (FDA), based on the results of the E4599 trial,
but the dosage of 7.5 mg/kg is not contraindicated by National
Comprehensive Cancer Network (NCCN) guidelines, according
to the results of AVAiL trial (63).
Despite the advantage in terms of increased OS and PFS,
the data published in literature about cost-benefit analysis are
not conclusive. A treatment containing bevacizumab is more
expensive compared to chemotherapy alone due to the high
cost of the drug, the longer duration of treatment,
bevacizumab being indicated for maintenance therapy, an
increased cost related to the longer OS, and the cost related
to the management of side-effects (73).
Conclusion
The topic covered in this review is still under much debate
and there is no common approach to first-line treatment with
bevacizumab for NSCLC. 
The results of pivotal studies, revealing an increase of OS
and of PFS, although of only a few months, argue in favor
of the use of this drug (15-17, 19-40). Other important
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aspects are the possibility of practicing a maintenance
treatment, increasing the time-to-disease progression and
improving the quality of life; the possibility of delaying the
start of a second-line treatment and the possibility of saving
effective treatments for successive lines, such as those based
on pemetrexed (1, 5).
On the other hand, the use of bevacizumab is related to
some adverse events, such as bleeding, thromboembolism,
hypertension and proteinuria. It is contraindicated in patients
with squamous histology and with recent bleeding (51), but
can be used with caution in patients receiving platelet
aggregation inhibitors or anti-coagulants, with bleeding or
thrombophilic diathesis, and in patients with untreated brain
metastases. These categories of patients, in fact, have been
excluded by the majority of previous clinical trials. Several
recent trials, however, have focused on demonstrating the
safety of this drug even in the categories of patients
previously excluded from clinical trials (45, 47-60).
Bevacizumab leads to a gain of about two months in terms
of OS. Therefore, it is not clear whether it is really appropriate
to choose such an expensive treatment burdened by many side-
effects to gain a rather small clinical benefit (1).
Another aspect to be taken into account is the absence of
factors predictive of response to treatment with bevacizumab,
differently to what occurs for other targeted agents, such as
gefitinib. Such factors of treatment response would allow us
to pursue a targeted therapeutic strategy, to reduce costs and
to not administer a drug burdened by toxicity to patients who
cannot benefit from it (63).
In conclusion, the possibility of practicing a treatment with
bevacizumab must be carefully analyzed case by case. As a
future perspective, it is important to identify patients who can
really benefit from the use of this molecular-targeted drug,
through identification of specific response markers and by the
identification of specific patient characteristics associated
with a best response to this treatment. Moreover, in light of
the results of recent clinical trials, it is important to analyze
new associations which could be effective and with
acceptable toxicity and that can also be used in elderly
patients and in therapy lines subsequent to the first.
Conflicts of Interest
The Authors declare that they have no conflicts of interest.
References
1 Bacellar Costa Lima A, Macedo LT and Deeke Sasse A:
Addition of bevacizumab to chemotherapy in advanced non-
small cell lung cancer: A systematic review and meta-analysis.
Plos One 6(8): e22681, 2011.
2 Stinchcombe TE and Socinski MA: Current treatments for
advanced stage non-small cell lung cancer. Proc Am Thorac Soc
6(2): 233-241, 2009.
3 Shiller JH, Harrington D, Belani CP, Langer C, Sandler A,
Krook J, Zhu J and Johnson DH: Comparison of four
chemotherapy regimens for advanced non-small cell lung cancer.
N Eng J Med 346(2): 92-98, 2002.
4 Gettinger S: Targeted therapy in advanced non-small cell lung
cancer. Semin Respir Crit Care Med 29(3): 291-301, 2009.
5 Ulahannan SV and Brahmer JR: Antiangiogenetic agents in
combination with chemotherapy in patients with advanced non-
small cell lung cancer. Cancer Investigation 29: 325-337, 2011.
6 Blau HM and Banfi A: The well-tempered vessel. Nat Med 7(5):
532-534, 2001.
7 Folkman J: What is the evidence that tumors are angiogenesis-
dependent? J Natl Cancer Inst 82(1): 4-6, 1990.
8 Folkman J: Angiogenesis: An organizing principle for drug
discovery? Nat Rev Drug Discov 6(4): 273-286, 2007.
9 Jain RK: Normalizing tumor vasculature with anti-angiogenetic
therapy. Nat Med 7(9): 987-989, 2001.
10 Ferrara N and Kerbel RS: Angiogenesis as a therapeutic target.
Nature 438(7070): 967-974, 2005.
11 Carmeliet P and Jain NK: Angiogenesis in cancer and other
diseases. Nature 407(6801): 249-257, 2000.
12 Carmeliet P: VEGF as a key mediator of angiogenesis in cancer.
Oncology 69(Suppl 3): 4-10, 2005.
13 Gridelli C, Maione P, Rossi A and De Marinis F: The role of
bevacizumab in the treatment of non-amall cell lung cancer:
Current indications and future developments. Oncologist 12:
1183-1193, 2007.
14 Jenab-Wolcott J and Giantonio BJ: Bevacizumab current
indications and future development for management of solid
tumors. Expert Opin Biol Ther 9(4): 507-517, 2009.
15 Johnson DH, Fehrenbacher L, Novotny WF, Herbst RS,
Nemunaitis JJ, Jablons DM, Langer CJ, DeVore RF, Graudreault
J, Damico LA, Holgren E and Kabbinavar F: Randomized phase
II trial comparing bevacizumab plus carboplatin and paclitaxel
with carboplatin and paclitaxel alone in previously untreated
locally advanced or metastatic non-small cell lung cancer. J Clin
Oncol 22(11): 2184-2191, 2004.
16 Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati
A, Lilenbaum R and Johnson DH: Paclitaxel-carboplatin alone
or with bevacizumab for non-small cell lung cancer. N Eng J
Med 355(24): 2542-2550, 2006.
17 Reck M, Von Pavel J, Zatloukal P, Ramlau R, Gorbounova V,
Hirsh V, Leighl, Mezger J, Archer V, Moore N and Manegold C:
Phase III trial of cisplatin plus gemcitabine with either placebo
or bevacizumab as first-line therapy for nonsquamous non-small
cell lung cancer: AVAiL. J Clin Oncol 27(8): 1227-1234, 2009.
18 Mezger J, Von Pavel J and Reck M: Bevacizumab (Bv) single
agent maintenance following Bv-based chemotherapy in patients
with advanced non-small cell lung cancer (NSCLC): Result from
an exploratory analysis of the AVAiL study. J Clin Oncol 27
(15S, May 20 suppl): Abstract e19001, 2009.
19 Patel JD, Hensing TARademaker A, Hart EM, Blum MG, Milton
DT and Bonomi PD: Phase II study of pemetrexed and
carboplatin plus bevacizumab with maintenance pemetrexed and
bevacizumab as first-line therapy for non-squamous non-small
cell lung cancer. J Clin Oncol 27(20): 3284-3289, 2009.
20 Patel J, Socinski MA, Garon EB, Reynolds CH, Spigel DR,
Hermann RC, Liu J, Guba SC, Bonomi P and Govindan R: A
randomized, open-label, phase 3, superiority study of
pemetrexed (Pem)+carboplatin (Cb)+bevacizumab (B) followed
ANTICANCER RESEARCH 34: 1537-1546 (2014)
1542
by maintenance Pem+B versus paclitaxel (Pac)+Cb+B followed
by maintenance B in patients (pts) with stage IIIB or IV non-
squamous non-small cell lung cancer (NS-NSCLC). J Thor
Oncol 7(15): S336-S338, 2012.
21 Socinski MA, Patel JD, Garon EB, Govindan R, Reynolds CH,
Spigel DR, Olsen MR, Liu J, Guba SC and Bonomi P: A phase
III study of pemetrexed (Pem) plus carboplatin (Cb) plus
bevacizumab (Bev) followed by maintenance Pem plus Bev
versus paclitaxel (Pac) plus Cb plus Bev followed by
maintenance Bev in stage IIIb or IV nonsquamous non-small cell
lung cancer (NS-NSCLC): Overall and age group results. J Clin
Oncol 31 (suppl; abstr 8004), 2013.
22 Barlesi F, De Castro J, Dvornichenko V, Kim JH, Pazzola A,
Rittmeyer A, Vikström A, Mitchell L, Wong EK and Gorbunova
V: AVAPERL (MO22089): Final efficacy outcomes for patients
(pts) with advanced non-squamous non-small cell lung cancer
(nsNSCLC) randomised to continuation maintenance (mtc) with
bevacizumab (Bev) or Bev + pemetrexed (Pern) after first-line
(1L) Bev-cisplatin (Cis)-Pem treatment (Tx). Eur J Cancer
47(Suppl 2): 16, 2011.
23 Rittemeyer A, Scherpereel A, Gorbunova VA, Gervais R,
Vikström A, Chouaid C, Chella A, Kim JH, Ahn MJ, Reck M,
Pazzola A, Kim HT, Aerts J, Groen HJM, Morando C, Loundou
A and Barlesi F: Effect of maintenance bevacizumab (Bev) plus
pemetrexed (Pem) after first-line cisplatin/Pem/Bev in advanced
nonsquamous non-small cell lung cancer (nsNSCLC) on overall
survival (OS) of patients (Pts) on the AVAPERL (MO22089)
phase III randomized trial. J Clin Oncol 31 (suppl; abstr 8014),
2013.
24 Skaff ZG, Hageboutros A, Krieger K, Coakley S, Somer R and
Stevenson J: A phase II trial of first-line bevacizumab in
combination with pemetrexed and carboplatin in advanced non-
squamous non-small cell lung cancer (NSCLC). J Clin Oncol
27(15S): Abstract e19091, 2009.
25 Dalsania CJ, Hageboutros A, Harris E, Krieger K, Vora C and
Stevenson J: Phase II trial of bevacizumab plus pemetrexed and
carboplatin in previously untreated advanced nonsquamous non-
small cell lung cancer. J Clin Oncol 25(18S): Abstract 18163,
2007.
26 Waples JM, Auerbach M, Steis R, Boccia RV and Wiggans RG:
A phase II study of oxaliplatin and pemetrexed plus
bevacizumab in advanced non-squamous non-small cell lung
cancer (An International Oncology Network study, #I-04-015).
J Clin Oncol 26(15S): Abstract 19018, 2008. 
27 Wozniak AJ, Kalemkerian GP, Gadgeel SM, Schneider BJ,
Valdivieso M, Venkatramanamoorthy R, Hackstock DM, Chen
W, Heilbrun LK and Ruckdeschel JD: A phase II trial of
pemetrexed (P), gemcitabine (G), and bevacizumab (BV) in
untreated patients (pts) with advanced non-small cell lung cancer
(NSCLC). J Clin Oncol 27(15S): Abstract e19099, 2009.
28 Lilebaum R, Racz L, Tseng J, Scigel L and Davila E: Efficacy
and safety of oxaliplatin and gemcitabine with bevacizumab in
advanced non-small cell lung cancer. J Thorac Oncol 3(5): 511-
515, 2008.
29 Leon L, Vazquez S Gracia JM, Lazaro M, Firvida JL, Casal J,
Amenedo M, Santome L, Gallego R and Anido U: Bevacizumab
(B), cisplatin, and vinorelbine in chemotherapy-naïve patients
(p) with nonsquamous non-small cell lung cancer (NSCLC): A
Galician Lung Cancer Group phase II study. J Clin Oncol
27(15S): Abstract e19089, 2009.
30 Herbst RS, O’Neill VJ, Fehrenbacher L, Belani CP, Bonomi PD,
Hart L, Melnyk O, Ramies D, Lin M and Sandler A: A phase II
study of efficacy and safety of bevacizumab in combination with
chemotherapy alone for treatment of recurrent or refractory non-
small cell lung cancer. J Clin Oncol 25(30): 4743-4750, 2007.
31 Ferrer N, Cobo M, Paredes A, Mendez M, Munoz-Langa J,
Rueda A, Alverez de Mon M, Sanchez-Hernandez A, Gallego R
and Torrego J: Phase II study of bevacizumab in combination
with cisplatin and docetaxel as first-line treatment of patients (p)
with metastatic nonsquamous non-small cell lung cancer
(NSCLC). J Clin Oncol 27(15S): Abstract e 19023, 2009.
32 Reynolds C, Barrera D, Jotte R, Spira AI, Weissman C, Boehm
KA, Pritchard S and Asmar L: Phase II trial of nanoparticle
albumin-bound paclitaxel, carboplatin, and bevacizumab in first-
line patients with advanced nonsquamous non-small cell lung
cancer. J Thorac Oncol 4(12): 1537-1543, 2009.
33 Clement-Duchene C, Krupitskaya Y, Ganjoo K, Lavori P, Mc
Millan A, Kumar A, Zhao G, Padda S, Zhou L, Pedro-Salcedo
MS, Colevas AD and Wakelee IIA: A phase II first-line study of
gemcitabine, carboplatin, and bevacizumab in advanced stage
nonsquamous non-small cell lung cancer. J Thorac Oncol 5(11):
1821-1825, 2010.
34 Bordonaro R, Soto-ParraH, Giannitto-Giorgio C, Cinieri S, Latteri
F, Sergi C, Pappagallo GL, Cordio SS, Salice P, Sambataro D and
Potenza E: Activity and safety of CPBev regimen (cisplatinum,
pemetrexed, and bevacizumab) as first-line therapy for locally
advanced or metastatic adenocarcinoma of the lung: finalresults
of a phase II study. J Clin Oncol 30 (suppl; abstr e18026), 2012.
35 Lopez-Vivanco G, Carrera S, Sancho A, Marrodan I, Azcona E,
Iruarrizaga E, Rubio I, Muñoz A and Cardona JV: Bevacizumab
(B), cisplatin (C), and pemetrexed (P) plus maintenance B in
chemonaive patients (pts) with advanced nonsquamous non-
small cell lung cancer (nsNSCLC): A phase II study. J Clin
Oncol 30 (suppl; abstr e18031), 2012.
36 Guarino MJ, Masters GA, Biggs D, Schneider C, Ghazi Misleh
J, Simpson PS, Suppiah K, Wozniak TF and Grubbs SS: Phase II
trial of carboplatin, pemetrexed, and bevacizumab in metastatic
nonsquamous (NSC) lung cancer. J Clin Oncol 30 (suppl; abstr
e18122), 2012.
37 Dy GK, Molina JR, Qi Y, Ansari RH, Thomas SP, Ross HJ, Meyers
jp, Adjei A, Mandrekar SJ and Adjei AA: N0821: a phase II first-
line study of a combination of pemetrexed (P), carboplatin (C) and
bevacizumab (B) in elderly patients with good performance status
(PS<2). J Clin Oncol 30 (suppl; abstr 7555), 2012.
38 West HJ, Moon J, Hirsch FR, Mack PC, Wozniak AJ, Lau D,
Fehrenbacher L, Joseph Bury M, Weber Redman M and
Gandara DR: SWOG S0635 and S0636: Phase II trial in
advanced-stage NSCLC of erlotinib (OSI-774) and bevacizumab
in bronchioloalveolar carcinoma (BAC) and adenocarcinoma
with BAC features (adenoBAC), and in never-smokers with
primary NSCLC adenocarcinoma (adenoCa). J Clin Oncol 30
(suppl; abstr 7517), 2012.
39 Yoshino R, Kaiara K, Tomizawa Y, Kazama T, Yoshii A, Miura
Y, Ishihara S, Fueki N, Minato K and Sunaga N: Phase II stidy
of bevacizumab in combination with S-1 plus cisplatin in
patients with advanced nonsquamous non-small cell lung cancer.
J Clin Oncol 30 (suppl; abstr e18037), 2012.
40 Kaneda H, Urata Y, Okamoto I, Hattori Y, Okuno K, Shimada T,
Takeda M, Kurata T, Miyazaki M, Terashima M, Tanaka K,
Kiyota H, Hayashi H, Kudo T, Okabe T, Azuma K, Morita S,
Lauro et al: Bevacizumab-based Treatment in NSCLC (Review)
1543
Nakagawa K, Negoro S and Satouchi M:: Oral S-1 and
carboplatin plus bevacizumab with maintenance S-1 and
bevacizumab for chemonaïve patients (Pts) with advanced non-
squamous non-small cell lung cancer (NSCLC). J Clin Oncol 30
(suppl; abstr e18060), 2012.
41 Ohyanagi F, Tanimoto A, Sakatani T, Kawano Y, Saito R,
Kaburaki K, Yanagitani N, Kudo K, Horiike A, Hagiwara S,
Horai T and Nishio M: Phase II trial of bevacizumab plus
docetaxel in patients with previously treated nonsquamous non-
small cell lung cancer. J Clin Oncol 30 (suppl; abstr e18004),
2012.
42 Habib S, Delourme J, Dhalluin X, Scherpereel A, Lafitte JJ and
Cortot AB: Weekly paclitaxel and bevacizumab as fourth-line
treatment or beyond for metastatic nonsquamous non-small cell
lung cancer. J Clin Oncol 30 (suppl; abstr e18066), 2012.
43 Gridelli C, Bennouna J, De Castro J, Dingemans AMC,
Griesinger F, Grossi F, Thatcher N, Ohe Y, Perez-Moreno PD
and Langer CJ: AvaALL: Open-label randomized phase IIIb trial
evaluating the efficacy and safety of standard of care with or
without continuous bevacizumab (BV) treatment beyond disease
progression in patients (pts) with advanced nonsquamous non-
small cell lung cancer (NSCLC) after first-line (1L) treatment
with BV plus platinum-doublet chemotherapy (CT). J Clin Oncol
30 (suppl; abstr TPS7612). 2012.
44 Cohen MH, Gootenberg J, Keegan P and Pazdur R: FDA drug
approval summary: bevacizumab (Avastin) plus carboplatin and
paclitaxel as first-line treatment of advanced/metastatic recurrent
nonsquamous non-small cell lung cancer. Oncologist 12(6): 713-
718, 2007.
45 Crino` L, Dansin E, Garrido P, GriesingerF, Laskin J, Pavlakis N,
Stroiakovski D, Thatcher N, Tsai CM, Wu YL and Zhou C:
Safety and efficacy of first-line bevacizumab-based therapy in
advanced non-squamous non-small cell lung cancer (SAiL,
MO19390): a phase 4 study. Lancet Oncol 11(8): 733-740, 2010.
46 Fishbach NA, Spigel D, Brahmer J, Garst J, Robles R, Chung C,
Wang L, Sing A and Lynch T, for the ARIES investigators:
Preliminary safety and effectiveness of bevacizumab (Bv)-based
treatment in subpopulation of patients (pts) with non-small cell
lung cancer (NSCLC) from the ARIES study: A bevacizumab Bv
treatment observational cohort study (OCS) J Clin Oncol
27(15S): Abstract 8040, 2009.
47 Polikoff J, Hainsworth JD, Fehrenbacher L, Royer-Joo S, Mu Y,
Strickland DK and Miller VA. Safety of bevacizumab (Bv)
therapy in combination with chemotherapy in subjects with non-
small cell lung cancer (NSCLC) treated on ATLAS. J Clin Oncol
26(15S): Abstract 8079, 2008.
48 Socinski MA, Langer CJ, Huang JE, Kolb MM, Compton P,
Wang L and Akerley W: Safety of bevacizumab in patients with
non-small cell lung cancer and brain metastases. J Clin Oncol
27: 5255-5261, 2009.
49 Otterson GA, O’Connor PG, Lin M and Herbst RS, for the
BETA Lung Investigators: Safety of bevacizumab (B) and
erlotinib (E) therapy in patients (pts) with treated brain
metastases (mets) in the phase III, placebo (P)-controlled,
randomized BeTa trial for pts with advanced non-small cell lung
cancer (NSCLC) after failure of standard first-line
chemotherapy. J Clin Oncol 27(15S): Abstract e19025, 2009.
50 Besse B, Le Moulec S, Senellart H, Mazieres J, Barlesi F,
Dansin E, Robinet G, Perol M, Moro-Sibilot D and Soria JC:
Final overall survival (OS) results of a noncomparative phase II
study of bevacizumab (B) plus first-line chemotherapy or
second-line erlotinib (E) in nonsquamous NSCLC (ns-NSCLC)
patients with asymptomatic untreated brain metastases (BM)
(BRAIN). J Clin Oncol 31 (suppl; abstr 8059), 2013.
51 Reck M, Barlesi F, Crinò L, Henschke CI, Isla D, Stiebeler S
and Spigel GL: Predicting and managing the risk of pulmonary
hemorrhage in patirnts with NSCLC treated with bevacizumab:
A consensus report from a panel of expert. Ann Oncol 23: 1111-
1120, 2012.
52 Hainsworth JD, Fang L, Huang JE, Karlin D, Russel K, Faoro L
and Azzoli C: BRIDGE: an open label phase IItrial evaluating
the safety of bevacizumab+ carboplatin/paclitaxel as first-line
treatment for patients with advanced, previously untreated
squamous non-small cell lung cancer. J Thorac Oncol 6: 109-
114, 2011.
53 Griesinger F, Bearz A, Eberhardt W, Garrido P, Isla D, Ko Y,
Kohlhaufl M, Schneider C, Thatcher T and Palakis N: Safety of
first line bevacizumab (BV)-based therapy in the SAiL
(MO19390) trial: Central trumor location (CTL) and
hypertension (HTN) in patients (PTS) with advanced non-small
cell lung cancer (NSCLC). Ann Oncol 21(Suppl 8): viii 144,
2010.
54 Kumar P, Fishbach NA, Brahmer JR, Spigel DR, Beatty S, Teng
S, Flick ED, Sing A and Lynch TJ: Baseline (BL) radiographic
characteristics and severe pulmonary hemorrhage (SPH) in
bevacizumab ((BV).treated non-small cell lung cancer (NSCLC)
patients (pt): results from ARIES, an observational cohort study
(OCS). J Clin Oncol 28(Suppl): 15s (Abstr 7619), 2010.
55 Sandler AB, Schiller JH, GrayR, Dimery I, Brahmer J, Samant
M, Wang LI and Johnson DH: Retrospective evaluation of the
clinical and radiographic risk factors associated with severe
pulmonary hemorrhage in first-line advanced, unresectable non-
small-cell lung cancer treated with carboplatin and paclitaxel
plus bevacizumab. J Clin Oncol 27: 1405-1412, 2009.
56 Marom EM, Martinez CH, Truong MT, Lei X, Sabloff BS,
Munden RF, Gladish GW, Herbst RS, Stewart DJ, Jimenez CA,
Blumenschein GR and Onn A: Tumor cavitation during therapy
with antiangiogenesis agents in patients with lung cancer. J
Thorac Oncol 3: 351-357, 2008.
57 Besse B, Laserre SF, Compton P, Huang J, Augustus S and Rohr
UP: Bevacizumab safety in patients with central nervous system
metastases. Clin Cancer Res 16: 269-278, 2010.
58 Hood JD, Meininger CJ, Ziche M and Granger HJ: VEGF up-
regulates ecNOS message, protein and NO production in human
endothelial cells. Am J Physiol 274: H1054-1058 (suppl 3),
1998.
59 Mourad JJ, Guetz G, Debbabi H and Levy BI: Blood pressure
rise following angiogenesis inhibition by bevacizumab: A crucial
role for microcirculation. Ann Oncol 19: 927-934, 2008.
60 Dahlberg SE, Sandler AB, Brahmer JR, Schiller JH and Johnson
DH: Clinical course of advanced non-small cell lung cancer
patients experiencing hypertension during treatment with
bevacizumab in combination with carboplatin and paclitaxel on
ECOG 4599. J Clin Oncol 28: 949-954, 2010.
61 Rini BI, Halabi S, Rosenberg JE, Stadler WM, Vaena DA,
Archer L, Atkins JN, Picus J, Czaykowski P, Dutcher J and
Small EJ: Phase III trial of bevacizumab plus interferon alfa
versus interferon alfa monotherapy in patients with metastatic
renal cell carcinoma: Final results of CALGB 90206. J Clin
Oncol 28(13): 2137-2143, 2010.
ANTICANCER RESEARCH 34: 1537-1546 (2014)
1544
62 Leighl NB, Zatloukal P, Mezger J, Ramlau R, Reck M and
Menegold C: Efficacy and safety of bevacizumab-based therapy
in elderly patients with advanced or recurrent nonsquamous non-
small cell lung cancer in the phase III BO17704 study (AVAIL).
J Thorac Oncol 5(12): 1970-1976, 2010.
63 Chun -Ru C and Ya-Chen TS: Economic evaluation of
bevacizumab in the treatment of non-small cell lung cancer
(NSCLC). Clin Econom Outcomes Res 4: 201-208, 2012.
64 Chouaid C, Atsou K, Hejblum G and Vergnenegre A: Economics
of treatments for non-small cell lung cancer. Pharmacoeconomics
27(2): 113-125, 2009.
65 Vergnenègre A, Ray JA, Chouaid C, Grossi F, Bischoff HG,
Heigener DF and Walzer S: Cross-market cost-effectiveness
analysis of erlotinib as first-line maintenance treatment for
patients with stable non-small cell lung cancer. Clinicoecon
Outcomes Res 4: 31-37, 2012.
66 Bongers ML, Coupé VM, Jansma EP, Smit EF and Uyl-de Groot
CA: Cost effectiveness of treatment with new agents in advanced
non-small cell lung cancer: A systematic review. Pharmaco-
economics 30(1): 17-34, 2012.
67 Isla D, González-Rojas N, Nieves D, Brosa M and Finnern HW:
Treatment patterns, use of resources, and costs of advanced non-
small cell lung cancer patients in Spain: Results from a Delphi
panel. Clin Transl Oncol 13(7): 460-471, 2011. 
68 Bischoff HG, Heigener DF, Walzer S and Nuijten M: Costs of
bevacizumab and pemetrexed for advanced non-squamous
NSCLC in Italy and Germany. Lung Cancer 69(Suppl 1): S18-
S23, 2010. 
69 Stanisic S, Bischoff HG, Heigener DF, Vergnenègre A, de
Castro Carpeño J, Chouaid C, Walzer S, Mueller E and Schmidt:
Societal cost savings through bevacizumab-based treatment in
non-small cell lung cancer (NSCLC). Lung Cancer 69(Suppl 1):
S24-S30, 2010. 
70 Klein R, Muehlenbein C, Liepa AM, Babineaux S, Wielage R
and Schwartzberg L: Cost-effectiveness of pemetrexed plus
cisplatin as first-line therapy for advanced nonsquamous non-
small cell lung cancer. J Thorac Oncol 4(11): 1404-1414, 2009.
71 Klein R, Wielage R, Muehlenbein C, Lepa AM, Babineaux S,
Lawson A and Schwartzberg L: Cost-effectiveness of pemetrexed
as first-line maintenance therapy for advanced nonsquamous non-
small cell lung cancer. J Thorac Oncol 5(8): 1263-1272, 2010.
72 Giuliani G, Grossi F, de Marinis F and Walzer S: Cost-
effectiveness analysis of bevacizumab versus pemetrexed for
advanced non-squamous NSCLC in Italy. Lung Cancer 69(Suppl
1): S11-S17, 2010. 
73 Ahn MJ, Tsai CM, Hsia TC, Wright E, Chang JWC, Kim JH,
Kang JH, Kim SW, Bae EJ, Kang M, Lister J and Walzer S:
Cost-effectiveness of bevacizumab-based therapy versus cisplatin
plus pemetrexed for the first-line treatment of advanced non-
squamous NSCLC in Korea and in Taiwan. Asia-Pacific J Clin
Oncol 7(suppl 2): 22-33, 2011.
74 Goulart B and Ramsey S: A trial-based assessment of the cost-
utility of bevacizumab and chemotherapy versus chemotherapy
alone for advanced non-small cell lung cancer. Value Health
14(6): 836-845, 2011. 
Received January 11, 2014
Revised February 8, 2014
Accepted February 10, 2014
Lauro et al: Bevacizumab-based Treatment in NSCLC (Review)
1545
